<DOC>
	<DOC>NCT02186119</DOC>
	<brief_summary>This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.</brief_summary>
	<brief_title>A Study of Abicipar Pegol in Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis of diabetes mellitus (Type 1 or 2) Decreased vision due to diabetic macular edema in at least 1 eye Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye Stroke or heart attack within the past 3 months History of vitrectomy, macular surgery, or glaucoma surgery in the study eye Cataract or refractive surgery in the study eye within the last 3 months Laser photocoagulation of the study eye within the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>